About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
Juristat_165
Juristat #8 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« Guest Post -- The Biggest Side-effect of Making Medicine | Main | Webinar on Confidentiality Agreements and Provisions »

October 01, 2015

Comments

Hey Andrew,

Still looks like there were no challenges by Achates, as Dave Boundy has astutely suggested, based on compliance with the APA, or other administrative law/procedure principles. We patent attorney folk need to remember that there is more to administrative law and procedure than just what's in the AIA (Abominable Inane Act) when it comes to challenging IPRs, including whether the PTAB has correctly followed those procedures under the APA and other relevant administrative law/procedure doctrines.

The comments to this entry are closed.

January 2018

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31